首页> 外文会议>Conference on advancing manufacture of cell and gene therapies >Greg Russotti to receive the 2019 Award for Advancing Manufacture of Cell and Gene Therapy
【24h】

Greg Russotti to receive the 2019 Award for Advancing Manufacture of Cell and Gene Therapy

机译:格雷格·鲁索蒂(Greg Russotti)因推动细胞和基因疗法的生产而获得2019年奖

获取原文

摘要

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and Engineering Conferences International are pleased to announce that Greg Russotti of Celgene is the recipient of the 2019 Award for Advancing Manufacture of Cell and Gene Therapy. The award will be presented at the Advancing Manufacture of Cell and Gene Therapy VI conference, January 27-31, 2019 in Coronado, California.Greg Russotti has established himself as a world leader in the field of cell therapy technical development and manufacturing. He joined Celgene over 12 years ago, just as Celgene began major efforts in the cell therapy field. He was initially responsible for process and analytical development of all cell-based processes at Celgene and was soon appointed CMC lead for Celgene's placental cell therapy product, PDA-001, with accountability for all technical operations activities, including process and analytical development, clinical production, quality control, quality assurance, and supply chain. Greg later took on functional responsibility for the aforementioned areas for all cell and tissue-based products.
机译:美国国家生物制造药物创新研究所(NIIMBL)和国际工程会议欣然宣布,Celgene的Greg Russotti荣获了2019年细胞和基因疗法先进制造奖。该奖项将在2019年1月27日至31日在加利福尼亚州科罗纳多举行的``细胞与基因疗法的先进制造VI''会议上颁发,格雷格·鲁索蒂(Greg Russotti)已确立了自己在细胞疗法技术开发和制造领域的全球领导者的地位。他在12年前加入Celgene,就在Celgene开始在细胞疗法领域做出重大努力时。他最初在Celgene负责所有基于细胞的过程的过程和分析开发,并很快被任命为Celgene胎盘细胞治疗产品PDA-001的CMC负责人,负责所有技术操作活动,包括过程和分析开发,临床生产,质量控制,质量保证和供应链。格雷格后来负责所有基于细胞和组织的产品在上述领域的职能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号